The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10A | Lipid modifying agents, plain | |
| 4 | C10AX | Other lipid modifying agents | |
| 5 | C10AX09 | Ezetimibe |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Ezetimibe |
Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EZETIMIBE SANDOZ Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| EZETROL Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| EZOLETA Tablet | Medicines Authority (MT) | MPI, EU: SmPC | |
| ZETIA Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ZIENT Tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
